GleamWall
中文EN

INCY INCYTE CORP

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 879169 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY24.9%
TTM net income YoY-66.1%
TTM EPS YoY-66.8%
Revenue 3-yr CAGR18.5%
Net income 3-yr CAGR-1.7%

Margins

Gross margin92.7%
Operating margin10.4%
Net margin6.7%
FCF margin—
EBITDA margin12.1%

Returns

ROE7.8%
ROA5.9%
ROIC (approx.)13.9%
Asset turnover0.88x

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.84x
Interest coverage267.97x

Cash quality & payout

Operating cash flow / net income1.85x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$5.14B$4.24B
Cost of revenue$372.13M$312.07M
Gross profit$4.77B$3.93B
R&D expense$2.05B$2.61B
SG&A expense$1.38B$1.24B
Operating income$1.51B$61.37M
Interest expense$2.43M$2.28M
Pretax income$1.66B$316.63M
Income tax$377.80M$284.01M
Net income$1.29B$32.62M
EBITDA$1.61B$150.61M
EPS (basic)6.590.16
EPS (diluted)6.410.15
Weighted avg. shares (diluted)200.70M210.53M
Balance sheet
Cash & equivalents$3.10B$1.69B
Inventory$101.06M$58.87M
Current assets$5.02B$3.24B
PP&E, net$730.88M$763.41M
Goodwill$133.00M$155.59M
Total assets$6.96B$5.44B
Current liabilities$1.52B$1.64B
Total liabilities$1.79B$2.00B
Shareholders' equity$5.17B$3.45B
Shares outstanding198.46M193.43M
Cash flow statement
Operating cash flow$1.41B$335.34M
Investing cash flow-$102.61M$157.52M
Financing cash flow$101.04M-$2.02B
Depreciation & amortization$93.29M$89.25M
Stock-based compensation$249.35M$266.06M
Share buybacks$0$2.00B

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.